Farah Champsi's Net Worth
Estimate Recalculated Dec 4, 2025 01:11AM EST
Who is Farah Champsi
Farah Champsi has an estimated net worth of $12.4 Million. This is based on reported shares across multiple companies, which include IMMUNE DESIGN CORP., COTHERIX INC, Population Health Investment Co., Inc., RENOVIS INC, ANESIVA, INC., ZS Pharma, Inc., NeurogesX Inc, Allakos Inc., Cara Therapeutics, Inc., CORCEPT THERAPEUTICS INC, SUTRO BIOPHARMA INC, Esperion Therapeutics, Inc., CHIMERIX INC, TREVENA INC, RIGEL PHARMACEUTICALS INC, Kite Pharma, Inc., APPLIED GENETIC TECHNOLOGIES CORP, SCYNEXIS INC, THRESHOLD PHARMACEUTICALS INC, aTYR PHARMA INC, SUNESIS PHARMACEUTICALS INC, Neothetics, Inc., TorreyPines Therapeutics, Inc., Aegerion Pharmaceuticals, Inc., PORTOLA PHARMACEUTICALS INC, ATS MEDICAL INC, INTARCIA THERAPEUTICS, INC, and ORPHAN MEDICAL INC.
SEC CIK
Farah Champsi's CIK is 0001198321
Past Insider Trading and Trends
2004 was Farah Champsi's most active year for acquiring shares with 2 total transactions. Farah Champsi's most active month to acquire stocks was the month of May. 2017 was Farah Champsi's most active year for disposing of shares, totalling 8 transactions. Farah Champsi's most active month to dispose stocks was the month of September. 2021 saw Farah Champsi paying a total of $10,781,250.00 for 43,125 shares, this is the most they've acquired in one year. In 2017 Farah Champsi cashed out on 156,884 shares for a total of $24,246,409.90, their largest year based on trade value.
Attention insiders:Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
